BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8968650)

  • 21. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diagnostic principles for differential therapy of psychoses].
    Hell D; Bridler R
    Praxis (Bern 1994); 2001 May; 90(22):975-80. PubMed ID: 11450185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 25. The evolving definition of treatment resistance.
    Peuskens J
    J Clin Psychiatry; 1999; 60 Suppl 12():4-8. PubMed ID: 10372602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 28. A prototype approach toward antipsychotic medication adherence in schizophrenia.
    Freudenreich O; Tranulis C
    Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The (new) definition of compliance].
    Arolt V
    Krankenpfl J; 2005; 43(7-10):214-5. PubMed ID: 16515287
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluating clinical trial data: outcome measures.
    Conley RR
    J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
    Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
    Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 34. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.
    van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS
    Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296
    [No Abstract]   [Full Text] [Related]  

  • 36. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study.
    Kulkarni AS
    Adv Biochem Psychopharmacol; 1974; 9(0):691-9. PubMed ID: 4151770
    [No Abstract]   [Full Text] [Related]  

  • 38. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 39. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnosis and treatment of children and adolescents with schizophrenia. "My mind is playing tricks on me".
    Kumra S
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):183-99, x. PubMed ID: 10674196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.